 |
 |
 |
 |
 |
9:00-9:40 John Kuriyan (UC Berkeley) Allosteric Control Mechanism in the Activation of the EGF Receptor
9:50-10:20 Kate Ferguson (UPenn) Mechanisms of inhibition of ligand-induced EGFR dimerization by therapeutic antibodies
10:30-11:00 Coffee break
11:00-11:40 David Cowburn (New York Structural Biology Center) Developing a dynamic structural view of protein tyrosine kinase regulation
11:50-12:20 Tomi Sawyer (Aileron Therapeutics) Exploring Chemical Space in Protein-Protein Interaction Drug Discovery
12:30-2:00 Lunch (provided by the Department of Pharmacology)
2:00-2:40 Stephen Burley (SGX Pharmaceutical) Discovery and development of selective, orally bioavailable tyrosine kinase inhibitors for targeted treatment of human cancers
2:50-3:20 Brian Blagg (U Kansas) Designing Old Drugs for New Targets, a Case Study with Novobiocin
3:30-4:00 Coffee break
4:00-4:40 Maurizio Pellecchia (Burnham) NMR- and fragment-based approaches to drug design
4:50-5:20 Rick Artis (Plexxikon) Scaffold-based Drug Discovery in Oncology
